GeneSort is a molecular diagnostics company focused on integrating molecular genomics with personalized therapeutic approaches. The company's mission is to use patients' genetic DNA profile to assist physicians in selecting safe, effective, tailored treatments.
GeneSort is focused on providing diagnostic services in the areas of cancer and hereditary diseases.
The company has been acquired in July 2018 by Hong Kong investment fund AID Partners for $23 million.
Cumulative Funding Raised Over Time ($)
Employees Over Time
GeneSort Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jul 16, 2018
pulsenews.co.kr
ACT to acquire Israel cancer molecular diagnosis company GeneSort for $17.8 mn - Pulse by Maeil Business News Korea